AKTS Aktis Oncology, Inc.
Fundamentals / CIK 0002035832 / USDAktis Oncology, Inc. reported $532.5M in total assets through September 30, 2026 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open AKTS in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2026-- Sep 30, 2026
-
Operating Income FY 2026-- Operating profit
-
Net Income FY 2026-- GAAP bottom line
-
Diluted EPS FY 2026-- Split-adjusted
-
Free Cash Flow FY 2026-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$68.32M Total debt: $10.84M
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Revenue | $3.90M | $3.38M | $3.23M | $1.58M | $1.60M | $1.45M |
| Research & Development | $32.12M | $25.28M | $20.04M | $16.47M | $18.63M | $15.86M |
| Total Operating Expenses | $38.65M | $32.28M | $25.93M | $19.78M | $22.56M | $19.59M |
| Operating Income | -$34.75M | -$28.90M | -$22.71M | -$18.20M | -$20.96M | -$18.14M |
| EBITDA | -$33.80M | -$28.02M | -$22.05M | -$17.61M | -$20.41M | -$17.66M |
| Interest Income | $4.82M | $4.76M | $4.38M | $2.68M | $2.91M | $3.17M |
| Net Income | -$29.94M | -$24.14M | -$18.32M | -$15.53M | -$18.07M | -$14.98M |
| Basic EPS | -$0.54 | -$0.44 | -$0.38 | -$19.18 | -$22.39 | -$18.60 |
| Diluted EPS | -$0.54 | -$0.44 | -$0.38 | -$19.18 | -$22.39 | -$18.60 |
| Basic Shares Outstanding | 55.6M | 55.3M | 48.6M | 809.8K | 807.3K | 805.8K |
| Diluted Shares Outstanding | 55.6M | 55.3M | 48.6M | 809.8K | 807.3K | 805.8K |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
| Cash & Cash Equivalents | $68.32M | $82.49M | $371.6M | $37.78M |
| Cash & Short-Term Investments | $492.9M | $517.3M | $538.5M | $37.78M |
| Total Current Assets | $499.9M | $524.5M | $543.9M | $230.3M |
| Property, Plant & Equipment, Net | $15.37M | $15.97M | $15.29M | $14.60M |
| Total Non-Current Assets | $32.60M | $33.06M | $32.86M | $34.58M |
| Total Assets | $532.5M | $557.6M | $576.8M | $264.9M |
| Accounts Payable | $1.44M | $2.53M | $1.23M | $1.74M |
| Deferred Revenue (Current) | $15.23M | $17.34M | $18.96M | $18.66M |
| Total Current Liabilities | $35.16M | $32.13M | $27.91M | $31.24M |
| Deferred Revenue (Non-Current) | $29.07M | $30.87M | $32.63M | $36.16M |
| Total Non-Current Liabilities | $38.45M | $40.63M | $42.78M | $46.39M |
| Total Liabilities | $73.61M | $72.76M | $70.69M | $77.62M |
| Total Debt (incl. Leases) | $10.84M | $11.24M | $11.58M | $11.55M |
| Retained Earnings | -$229.0M | -$199.0M | -$174.9M | -$156.6M |
| Accumulated Other Comp. Income | -$1.93M | -$745K | -$241K | $42K |
| Total Stockholders' Equity | $458.9M | $484.8M | $506.1M | -$146.1M |
| Total Equity | $458.9M | $484.8M | $506.1M | -$146.1M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Net Income | -$29.94M | -$24.14M | -$18.32M | -$15.53M | -$18.07M | -$14.98M |
| Depreciation & Amortization | $942K | $879K | $652K | $598K | $552K | $484K |
| Stock-Based Compensation | $3.45M | $3.22M | $3.02M | $1.28M | $1.52M | $1.24M |
| Change in Payables | -$667K | $866K | -$65K | $392K | -$115K | $90K |
| Operating Cash Flow | -$26.05M | -$20.59M | -$24.24M | -$15.22M | -$16.18M | -$17.48M |
| Capital Expenditure | -$772K | -$1.26M | -$1.85M | -$2.00M | -$1.53M | -$1.89M |
| Free Cash Flow | -$26.82M | -$21.85M | -$26.10M | -$17.23M | -$17.71M | -$19.38M |
| Purchases of Investments | -$56.24M | -$300.4M | $0 | $0 | $0 | -$10.82M |
| Investing Cash Flow | $10.17M | -$268.7M | $20.54M | $85.23M | $68.14M | $39.04M |
| Common Stock Issued | -- | -- | $5.38M | -- | -- | -- |
| Financing Cash Flow | $1.71M | $156K | $337.5M | $28K | $0 | -$468K |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Current Ratio | 14.22x | 16.33x | 19.49x | -- | -- | -- |
| Quick Ratio | 14.02x | 16.10x | 19.29x | -- | -- | -- |
| Debt to Equity | 0.02x | 0.02x | 0.02x | -- | -- | -- |
| Revenue Growth (YoY) | +147.3% | +111.4% | +123.0% | -- | -- | -- |